ATE265433T1 - Verbesserte matrix-metallprotease-inhibitoren - Google Patents
Verbesserte matrix-metallprotease-inhibitorenInfo
- Publication number
- ATE265433T1 ATE265433T1 AT92901322T AT92901322T ATE265433T1 AT E265433 T1 ATE265433 T1 AT E265433T1 AT 92901322 T AT92901322 T AT 92901322T AT 92901322 T AT92901322 T AT 92901322T AT E265433 T1 ATE265433 T1 AT E265433T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- protease inhibitors
- matrix metal
- image
- aryl
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- -1 cyclic amine Chemical class 0.000 abstract 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/615,798 US5183900A (en) | 1990-11-21 | 1990-11-21 | Matrix metalloprotease inhibitors |
| US07/747,752 US5189178A (en) | 1990-11-21 | 1991-08-20 | Matrix metalloprotease inhibitors |
| PCT/US1991/008723 WO1992009556A1 (en) | 1990-11-21 | 1991-11-21 | Improved matrix metalloprotease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE265433T1 true ATE265433T1 (de) | 2004-05-15 |
Family
ID=27087601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92901322T ATE265433T1 (de) | 1990-11-21 | 1991-11-21 | Verbesserte matrix-metallprotease-inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5189178A (de) |
| EP (1) | EP0558648B1 (de) |
| JP (1) | JP2736285B2 (de) |
| AT (1) | ATE265433T1 (de) |
| AU (1) | AU662504B2 (de) |
| CA (1) | CA2096221A1 (de) |
| DE (1) | DE69133385T2 (de) |
| WO (1) | WO1992009556A1 (de) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| US5239078A (en) * | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| AU2228292A (en) * | 1991-06-14 | 1993-01-12 | Research Corporation Technologies, Inc. | Peptide derivatives of collagenase inhibitor |
| EP0642353A1 (de) * | 1992-05-14 | 1995-03-15 | Oncologix, Inc. | Behandlung des vaskularen permeabilitätssyndroms und der kollagenase induzierten krankheit durch administrieren von inhibitoren der matrix-metalloproteinase(20.01.94) |
| GB9213473D0 (en) * | 1992-06-25 | 1992-08-12 | Hoffmann La Roche | Hydroxamic acid derivatives |
| AU666727B2 (en) * | 1992-06-25 | 1996-02-22 | F. Hoffmann-La Roche Ag | Hydroxamic acid derivatives |
| CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
| US6013792A (en) * | 1993-08-05 | 2000-01-11 | Syntex (U.S.A.), Inc. | Matrix metalloprotease inhibitors |
| US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
| US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
| UA48121C2 (uk) * | 1993-11-04 | 2002-08-15 | Сінтекс (С.Ш.А.) Інк. | Інгібітори матричних металопротеаз і фармацетична композиція на їх основі |
| US5476939A (en) * | 1993-12-30 | 1995-12-19 | Abbott Laboratories | Certain pyridyl and isoquinolyl carbinolamine derivatives |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| GB9411088D0 (en) * | 1994-06-03 | 1994-07-27 | Hoffmann La Roche | Hydroxylamine derivatives |
| GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
| GB9416897D0 (en) * | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
| JP3505274B2 (ja) * | 1994-08-25 | 2004-03-08 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| JPH08114884A (ja) * | 1994-08-25 | 1996-05-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| US5639746A (en) * | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
| ES2233275T3 (es) * | 1995-12-08 | 2005-06-16 | Agouron Pharmaceuticals, Inc. | Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas. |
| US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| ATE225343T1 (de) * | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| ATE226573T1 (de) | 1996-08-28 | 2002-11-15 | Procter & Gamble | Heterozyklische metalloproteaseinhibitoren |
| DE69716934T2 (de) * | 1996-08-28 | 2003-07-31 | The Procter & Gamble Company, Cincinnati | 1,3-diheterozyklische metalloprotease inhibitoren |
| BR9713182A (pt) * | 1996-08-28 | 1999-11-03 | Procter & Gamble | Amidas de ácido fosfìnico como inibidores de metalo protease de matriz |
| RU2203274C2 (ru) * | 1996-08-28 | 2003-04-27 | Дзе Проктер Энд Гэмбл Компани | Спироциклические ингибиторы металлопротеаз |
| KR100339296B1 (ko) * | 1996-08-28 | 2002-06-03 | 데이비드 엠 모이어 | 헤테로고리성 메탈로프로테아제 억제제 |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| WO1998036742A1 (en) * | 1997-02-25 | 1998-08-27 | The Regents Of The University Of Michigan | Methods and compositions for preventing and treating chronological aging in human skin |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| CA2298617A1 (en) | 1997-07-31 | 1999-02-11 | Yetunde Olabisi Taiwo | Acyclic metalloprotease inhibitors |
| GB9818605D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therepeutic agents |
| US6329400B1 (en) | 1998-08-26 | 2001-12-11 | Glaxo Wellcome Inc. | Formamide compounds as therapeutic agents |
| US6172064B1 (en) | 1998-08-26 | 2001-01-09 | Glaxo Wellcome Inc. | Formamides as therapeutic agents |
| US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| BR0008716A (pt) | 1999-03-03 | 2002-09-24 | Procter & Gamble | Inibidores de metaloprotease contendo alquenil ou alquinil |
| IL161057A0 (en) * | 2001-09-25 | 2004-08-31 | Quick Med Technologies Inc | Composition and method for minimizing or avoiding adverse effects of vesicants |
| AU2003233154A1 (en) | 2002-06-10 | 2003-12-22 | Pfizer Inc. | Metabolites of prinomastat and their sythesis |
| AU2003257089A1 (en) * | 2002-07-31 | 2004-02-16 | University Of Florida | Antimicrobial and antiproteolytic wound dressing |
| US20080139512A1 (en) * | 2002-09-25 | 2008-06-12 | Quick-Med Technologies, Inc. | Method for minimizing or avoiding adverse effects of vesicants |
| US20040192658A1 (en) * | 2002-12-27 | 2004-09-30 | Angiotech International Ag | Compositions and methods of using collajolie |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| ATE517926T1 (de) | 2003-04-04 | 2011-08-15 | Yeda Res & Dev | Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 |
| EP2287326A1 (de) | 2003-08-08 | 2011-02-23 | Arriva Pharmaceuticals, Inc. | Verfahren zur Protein-Produktion in Hefe |
| IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
| EP1737499A4 (de) | 2004-03-09 | 2009-07-22 | Arriva Pharmaceuticals Inc | Behandlung von chronisch obstruktiver lungenerkrankung durch inhalation von niedrigen dosen eines proteasehemmers |
| WO2006009325A1 (ja) * | 2004-07-23 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | メタロプロテアーゼ阻害剤 |
| GB0421308D0 (en) * | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
| EP2200628A2 (de) | 2007-07-15 | 2010-06-30 | Yitzchak Hillman | Behandlung von krankheiten über antimikrobielle peptide oder ihre inhibitoren |
| KR20100071972A (ko) | 2007-08-15 | 2010-06-29 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Ｍｍｐ-9의 조절인자 및 그의 용도 |
| GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
| US20090209447A1 (en) | 2008-02-15 | 2009-08-20 | Michelle Meek | Cleaning compositions |
| EP2296705A1 (de) * | 2008-06-24 | 2011-03-23 | Hadasit Medical Research Services And Development Ltd. | Ccl20-spezifische antikörper für die krebstherapie |
| ES2349972B1 (es) | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas. |
| BR112012000531A2 (pt) | 2009-07-09 | 2019-09-24 | Procter & Gamble | composição detergente para lavagem de roupas catalítica que compreende teores relativamente baixos de eletrólito solúvel em água |
| WO2011005730A1 (en) | 2009-07-09 | 2011-01-13 | The Procter & Gamble Company | A catalytic laundry detergent composition comprising relatively low levels of water-soluble electrolyte |
| CA2787311C (en) | 2010-01-27 | 2017-08-15 | Yeda Research And Development Co. Ltd. | Antibodies that inhibit metalloproteins |
| WO2011151833A1 (en) | 2010-06-03 | 2011-12-08 | Ramot At Tel-Aviv University Ltd. | Methods of treating diabetes and compositions capable of same |
| US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
| WO2012056455A1 (en) | 2010-10-28 | 2012-05-03 | Yeda Research And Development Co. Ltd. | Methods of generating antibodies to metalloenzymes |
| US9061006B2 (en) | 2011-03-08 | 2015-06-23 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (PKU) |
| CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
| EP3191523B1 (de) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Zusammensetzungen und verfahren zur behandlung von krebs mit resistenz gegenüber einem tyrosinkinasehemmer (tki) |
| EP3261582B1 (de) | 2015-02-26 | 2021-01-06 | Remodeless CV Ltd. | Verfahren und zusammensetzungen in zusammenhang mit leptin-antagonisten |
| EP3294280A1 (de) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrinhemmer zur behandlung von krebs |
| WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
| EP3176183A1 (de) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki) |
| EP3403091B1 (de) | 2016-01-11 | 2021-12-22 | Technion Research & Development Foundation Limited | Verfahren zur bestimmung der prognose von sepsis und behandlung davon |
| WO2017175228A1 (en) | 2016-04-06 | 2017-10-12 | Technion Research & Development Foundation Limited | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies |
| IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
| JP7542529B2 (ja) | 2018-10-17 | 2024-08-30 | バイオラインアールエックス・リミテッド | 転移性膵臓腺癌の処置 |
| IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof |
| US12509512B2 (en) | 2019-06-27 | 2025-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3A antibodies and uses thereof |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| BR112022007299A2 (pt) * | 2019-10-15 | 2022-07-05 | Ophirex Inc | Gestão precoce, mitigação e prevenção da sepse e síndromes semelhantes à sepse, incluindo ards neonatal por causa de infecção, lesão ou iatrogênese |
| IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
| IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| WO2022269605A1 (en) | 2021-06-24 | 2022-12-29 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| IT202100023357A1 (it) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| EP4584297A1 (de) | 2022-09-11 | 2025-07-16 | Yeda Research and Development Co. Ltd | Anti-klk4-antikörper und verwendungen davon |
| GB202316777D0 (en) | 2023-11-01 | 2023-12-13 | Cambridge Entpr Ltd | New therapeutic use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291048A (en) * | 1978-07-06 | 1981-09-22 | Joseph Gold | Method of treating tumors and cancerous cachexia with L-tryptophan |
| JPS5758626A (en) * | 1980-09-26 | 1982-04-08 | Rikagaku Kenkyusho | Carcinostatic agent |
| GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| US4558034A (en) * | 1984-01-31 | 1985-12-10 | The Board Of Trustees Of The University Of Kentucky | Inhibitors of bacterial collagenase |
| DE3482590D1 (de) * | 1984-04-12 | 1990-08-02 | Searle & Co | Carboxyalkyl-peptid-derivate. |
| US4698342A (en) * | 1985-07-16 | 1987-10-06 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| US4681894A (en) * | 1986-09-26 | 1987-07-21 | Ortho Pharmaceutical Corporation | Hydroxamic acids and esters |
| ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
| FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
| ATE106087T1 (de) * | 1987-03-17 | 1994-06-15 | Res Corp Technologies Inc | Synthetische inhibitoren von säugetier- collagenase. |
| CA1337400C (en) | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US4943587A (en) * | 1988-05-19 | 1990-07-24 | Warner-Lambert Company | Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition |
| US5114953A (en) * | 1990-11-21 | 1992-05-19 | University Of Florida | Treatment for tissue ulceration |
| US5239078A (en) * | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| ES2069833T3 (es) * | 1990-12-03 | 1995-05-16 | Celltech Ltd | Derivados peptidilicos. |
-
1991
- 1991-08-20 US US07/747,752 patent/US5189178A/en not_active Expired - Lifetime
- 1991-11-21 CA CA002096221A patent/CA2096221A1/en not_active Abandoned
- 1991-11-21 JP JP4501548A patent/JP2736285B2/ja not_active Expired - Lifetime
- 1991-11-21 AU AU90958/91A patent/AU662504B2/en not_active Ceased
- 1991-11-21 DE DE69133385T patent/DE69133385T2/de not_active Expired - Lifetime
- 1991-11-21 EP EP92901322A patent/EP0558648B1/de not_active Expired - Lifetime
- 1991-11-21 WO PCT/US1991/008723 patent/WO1992009556A1/en not_active Ceased
- 1991-11-21 AT AT92901322T patent/ATE265433T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5189178A (en) | 1993-02-23 |
| EP0558648B1 (de) | 2004-04-28 |
| AU662504B2 (en) | 1995-09-07 |
| JPH05508163A (ja) | 1993-11-18 |
| WO1992009556A1 (en) | 1992-06-11 |
| DE69133385D1 (de) | 2004-06-03 |
| JP2736285B2 (ja) | 1998-04-02 |
| DE69133385T2 (de) | 2005-02-24 |
| AU9095891A (en) | 1992-06-25 |
| EP0558648A1 (de) | 1993-09-08 |
| EP0558648A4 (en) | 1993-11-24 |
| CA2096221A1 (en) | 1992-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69133385D1 (de) | Verbesserte matrix-metallprotease-inhibitoren | |
| ATE157963T1 (de) | Verbesserte matrix metallprotease inhibitoren | |
| DE69129236D1 (de) | Behandlung für gewebeulzerationen | |
| DK0513379T3 (da) | 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne | |
| NO914356D0 (no) | Mono n-substituerte 1,4,7,10-tetraazacyklododecan-derivater | |
| FR2725986B1 (fr) | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| YU86801A (sh) | Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga | |
| ATE299861T1 (de) | Ppar-(gamma) agonisten zur behandlung von type ii diabetes | |
| NO943744L (no) | Fremgangsmåte for å ödelegge merkaptaner, samt fremstilling av kvaternære ammoniumhydroksyder for dette formål | |
| FR2764890B1 (fr) | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| DK300680A (da) | 5-amino-2,4,6-trijodisophtal-syre-bisamider og fremgangsmaade til fremstilling heraf samt anvendelse heraf i roentgenkontrastmidler | |
| ATE137757T1 (de) | Gem-diphosphonsäuren, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
| ES2057216T3 (es) | N-(1,4-benzodiazepin-3-il) amidas de acidos 1h-indol-2-carboxilicos condensados en posiciones 1,7. | |
| PE20001241A1 (es) | Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores | |
| ATE213496T1 (de) | Heterozyclische verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| PL323339A1 (en) | Novel benzopyranic compounds, method of obtaining them and pharmaceutic compositions containing such compounds | |
| DK0588797T3 (da) | N- 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracen-yl carbonyl aminosyrer nyttige ved behandling af osteoartikulære lidelser | |
| FR2609603B1 (fr) | Agents edulcorants derives des acides guanidinoacetique et ethanamidinoacetique, procede pour edulcorer des produits divers, et compositions contenant de tels agents edulcorants | |
| NO931844L (no) | Forbedrede matriks metallproteasehemmere | |
| NO931841L (no) | Forbedrede matriksmetallproteasehemmere | |
| ID21677A (id) | Proses pembuatan n-[2-(dimetilamino)etil]-akridin-4-karboksamida | |
| ATE221530T1 (de) | Verfahren zur n-alkylierung von cyclischen cyanamidinen | |
| NO931803L (no) | Behandling av vevsulkerasjon | |
| ATE96026T1 (de) | Verwendung heterozyklischer amide zur verhinderung der tumormetastasierung. | |
| DE69333270D1 (de) | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |